Neovascular age-related macular degeneration (nAMD), also called "wet" AMD, is when new blood vessels grow in the retina, the light-sensitive part of the eye. This study tests a new gene therapy called Surabgene Lomparvovec to see if it helps people with nAMD. People aged 50 and older who have been treated for nAMD before can join. About 561 people from around the world will be in the study.
Participants will be put into 3 groups. Two groups will get a single injection of the gene therapy, and the third group will get another treatment called Ranibizumab, which is given as needed. The study lasts up to 5 years, and participants will have monthly check-ups to see how the treatment is working and if there are any side effects.
- The study may require more visits and treatments than regular care.
- Participants will have monthly visits for up to 5 years.
- Regular check-ups include medical assessments, blood tests, and questionnaires.
How understandable was the trial content above?
Hard to understand
Easy to understand